Clinical trials: Psoriasis Patients
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
The purpose of this study is to document quality of life, patient satisfaction, effect on itching, and control of psoriasis vulgaris associated with use of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension…
- Trial name
- NCT01982552
- Where
- 12 sites in United States
- Volunteers
- 147 people
- Sponsor
- LEO Pharma
HIV Infections, Psoriasis
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination…
- Trial name
- NCT00002143
- Testing
- Acitretin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Pediatric Psoriasis
Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis
Enbrel was first approved as new medicine on 06 Oct 2003 in Korea and the indication of Pediatric Psoriasis was approved on 23 Sep 2009.
- Trial name
- NCT01432249
- Testing
- Enbrel group
- Sponsor
- Pfizer
Psoriatic Arthritis
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
This study was designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in…
- Trial name
- PDUS (NCT02662985)
- Testing
- AIN457 (secukinumab)
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Plaque Psoriasis
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.
- Trial name
- NCT01875991
- Testing
- Etanercept via Autoinjector A, Etanercept via Autoinjector B
- Where
- 37 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Amgen
Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris.
- Trial name
- NCT00817219
- Testing
- Calcipotriene plus betamethasone dipropionate ointment
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- LEO Pharma
Psoriasis, Plaque Psoriasis
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an…
- Trial name
- NCT05725057
- Testing
- AX-158
- Where
- 6 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Artax Biopharma Inc
Psoriasis
Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database
The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan.
- Trial name
- NCT01081730
- Testing
- anti-TNF biologics, general population, non-anti-TNF biologics
- Volunteers
- 2,040 people
- Sponsor
- Janssen Biotech, Inc.
Psoriasis
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in…
- Trial name
- NCT06477237
- Testing
- HB0017 Q4W, HB0017 Q8W
- Where
- 44 sites in China
- Volunteers
- 408 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Plaque Psoriasis
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.
- Trial name
- ESTEEM 1 (NCT01194219)
- Testing
- Apremilast, Topical treatments or phototherapy
- Volunteers
- 844 people
- Sponsor
- Amgen
Psoriasis Vulgaris
Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis
The main objective of this study is to establish the efficacy and safety of Psorax35 supplementation in patients with mild to moderate Psoriasis.
- Trial name
- NCT03359577
- Testing
- Psorax35, MCT oil
- Where
- Norway
- Volunteers
- 64 people
- Sponsor
- Arctic Nutrition AS
Psoriasis
Intervention Study to Evaluate a Probiotic in Mild to Moderate Psoriasis Patients
This study evaluates the efficiency of a probiotic as a coadjuvant in the conventional treatment of mild to moderate plaque psoriasis.
- Trial name
- NCT02576197
- Testing
- Probiotic
- Where
- Spain
- Volunteers
- 98 people
- Sponsor
- Biopolis S.L.
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
Psoriasis
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03556202
- Testing
- Mirikizumab
- Where
- 229 sites in United States, Argentina and 17 more
- Volunteers
- 1,936 people
- Sponsor
- Eli Lilly and Company
Moderate-to-Severe Plaque Psoriasis
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in Patients with Moderate-to-Severe Plaque Psoriasis
- Trial name
- NCT04839016
- Testing
- SHR-1314
- Volunteers
- 660 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Psoriasis
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants…
- Trial name
- NCT02672852
- Testing
- Risankizumab
- Volunteers
- 507 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])
A special investigation (post marketing observational study [PMOS]/non-mandatory) of HUMIRA® in Japanese psoriatic arthritis patients who are engaged in paid work.
- Trial name
- NCT02414633
- Volunteers
- 148 people
- Sponsor
- AbbVie
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor…
- Trial name
- IZAR-2 (NCT06641089)
- Testing
- Sonelokimab, Risankizumab
- Where
- 143 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- MoonLake Immunotherapeutics AG
Plaque Psoriasis
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany
The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year…
- Trial name
- DELPHIN (NCT06104644)
- Testing
- Deucravacitinib
- Where
- 2 sites in Germany
- Volunteers
- 550 people
- Sponsor
- Bristol-Myers Squibb